Latest news with #Failure-to-FileCeaseTradeOrder
Toronto Star
08-08-2025
- Business
- Toronto Star
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order
Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) — Aja Health and Wellness Inc. ('Aja' or the 'Company') (TSXV:Aja) announces that the Alberta Securities Commission (the 'ASC'), as its principal regulator, has revoked the management cease trade order previously issued to the Company. On August 1, 2025, the ASC issued a Failure-to-File Cease Trade Order (the 'FFCTO') prohibiting the trading by any person of any securities of the Company.
Montreal Gazette
08-08-2025
- Business
- Montreal Gazette
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order
Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities Commission (the " ASC"), as its principal regulator, has revoked the management cease trade order previously issued to the Company. On August 1, 2025, the ASC issued a Failure-to-File Cease Trade Order (the " FFCTO") prohibiting the trading by any person of any securities of the Company. The FFCTO was issued due to the delayed filing of the Company's annual audited financial statements for the financial year ending December 31, 2024, including the related management's discussion and analysis and certifications from the CEO and CFO (the " Annual Filings") and the Company's unaudited interim financial statements for the three months ended March 31, 2025, the management's discussion and analysis for the same period and management certifications of the interim filings (the " Interim Filings") beyond the April 30, 2025 and May 30, 2025 deadline for the Annual Filings and Interim Filings, respectively. The Company anticipates that the FFCTO will remain in place until such time as the Annual Filings and the Interim Filings are filed. Update on Annual Filings Aja previously announced that the delay in filing the Annual Filings was due to the determination that the previously announced reverse takeover transaction, which closed on September 17, 2024, will be characterized as a series of acquisitions for accounting purposes. This characterization requires a valuation of the purchase price allocation to complete the audited financial statements for the financial year ending December 31, 2024. The valuator continues to work on valuing the purchase price allocation and anticipates having the valuation finalized on or before August 15, 2025. Following receipt of the valuation, the auditors will continue working with the Company to complete the audited financial statements for the financial year ending December 31, 2024. The Company is working to complete the Annual Filings as soon as possible and expects the Annual Filings to be filed on or before August 29, 2025. Update on Interim Filings As a result of the delay in filing the Annual Filings, Aja previously announced that it was unable to file its Interim Filings. Aja is working to complete the Interim Filings as soon as possible and expects the Interim Filings to be filed on or before August 29, 2025. On behalf of the Board of Directors "Sanjeev Parsad" Sanjeev Parsad President, CEO and Director The above may contain "forward-looking information" within the meaning of applicable securities laws. When used in this address, the words "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although the Company believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, readers are cautioned to not place undue reliance on forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date of publication of this information and the Company undertakes no obligation to update such forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Furthermore, the Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, contact: This story was originally published August 8, 2025 at 6:28 PM.
Yahoo
24-06-2025
- Business
- Yahoo
LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading On TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its news release of June 23, 2025, the Ontario Securities Commission (the "OSC") has revoked a Failure-to-File Cease Trade Order (the "FFCTO") that had been originally issued by the OSC against the Company on May 7, 2025. The Company is now current on its continuous disclosure obligations under securities legislation. As also previously announced, the Company is in the process of applying to the TSX Venture Exchange for reinstatement of trading in its common shares. A news release will be issued prior to the resumption of trading. About LevelJump Healthcare LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve. ON BEHALF OF THE BOARD OF DIRECTORS OFLEVELJUMP HEALTHCARE CORP. Mitchell GeislerChief Executive Officerinfo@ CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable). Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction. To view the source version of this press release, please visit
Ottawa Citizen
28-04-2025
- Business
- Ottawa Citizen
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
Article content QUEBEC CITY — Devonian Health Group Inc. (' Devonian ' or the ' Company ') (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the ' Exchange ') has approved its application for reinstatement of trading of the Company's common shares on the Exchange effective April 30, 2025. This follows the successful resolution of the Failure-to-File Cease Trade Order (the ' FFCTO ') issued by the Autorité des marchés financiers (the ' AMF ') on April 7, 2025, and revoked on April 16, 2025. Article content Article content Article content The FFCTO was issued as a result of the delay in filing the Company's interim financial statements for the fiscal quarter ended January 31, 2025, its management's discussion and analysis for the fiscal quarter ended January 31, 2025, and related filings (collectively, the ' Required Interim Filings '). The Company filed the Required Interim Filings on April 15, 2025, upon which to the AMF had the FFCTO revoked on which the Exchange allowed the Company's common shares to resume trading. Article content The Company acknowledges and appreciates the patience of its shareholders and stakeholders during this process and reaffirms its commitment to adhering to high standards of compliance and corporate governance. Article content About Devonian Article content Devonian Health Group is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Article content Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Article content Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the Exchange (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). Article content All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the timing of reinstatement of the common shares on the Exchange, and, generally, the above 'About Devonian' and 'About Altius' paragraphs, which essentially describes the Company's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Article content Article content Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Article content By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Article content Article content Article content Article content Article content Contacts Article content
National Post
28-04-2025
- Business
- National Post
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
Article content QUEBEC CITY — Devonian Health Group Inc. (' Devonian ' or the ' Company ') (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the ' Exchange ') has approved its application for reinstatement of trading of the Company's common shares on the Exchange effective April 30, 2025. This follows the successful resolution of the Failure-to-File Cease Trade Order (the ' FFCTO ') issued by the Autorité des marchés financiers (the ' AMF ') on April 7, 2025, and revoked on April 16, 2025. Article content Article content The FFCTO was issued as a result of the delay in filing the Company's interim financial statements for the fiscal quarter ended January 31, 2025, its management's discussion and analysis for the fiscal quarter ended January 31, 2025, and related filings (collectively, the ' Required Interim Filings '). The Company filed the Required Interim Filings on April 15, 2025, upon which to the AMF had the FFCTO revoked on which the Exchange allowed the Company's common shares to resume trading. Article content The Company acknowledges and appreciates the patience of its shareholders and stakeholders during this process and reaffirms its commitment to adhering to high standards of compliance and corporate governance. Article content Devonian Health Group is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Article content Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Article content Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the Exchange (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). Article content All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the timing of reinstatement of the common shares on the Exchange, and, generally, the above 'About Devonian' and 'About Altius' paragraphs, which essentially describes the Company's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Article content Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Article content By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
